Literature DB >> 25301052

Lin28/let-7 axis regulates aerobic glycolysis and cancer progression via PDK1.

Xiaoyu Ma1, Chenchen Li1, Linchong Sun1, De Huang1, Tingting Li1, Xiaoping He1, Gongwei Wu1, Zheng Yang1, Xiuying Zhong1, Libing Song2, Ping Gao1, Huafeng Zhang1.   

Abstract

Aberrant expression of Lin28 and let-7 has been observed in many human malignancies. However, its functions and underlying mechanisms remain largely elusive. Here we show that aberrant expression of Lin28 and let-7 facilitates aerobic glycolysis, or Warburg effect, in cancer cells. Mechanistically, we discover that Lin28A and Lin28B enhance, whereas let-7 suppresses, aerobic glycolysis via targeting pyruvate dehydrogenase kinase 1, or PDK1, in a hypoxia- or hypoxia-inducible factor-1 (HIF-1)-independent manner, illustrating a novel pathway to mediate aerobic glycolysis of cancer cells even in ambient oxygen levels. Importantly, we further demonstrate that PDK1 is critical for Lin28A- and Lin28B-mediated cancer proliferation both in vitro and in vivo, establishing a previously unappreciated mechanism by which Lin28/let-7 axis facilitates Warburg effect to promote cancer progression. Our findings suggest a potential rationale to target PDK1 for cancer therapy in malignancies with aberrant expression of Lin28 and let-7.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25301052     DOI: 10.1038/ncomms6212

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  74 in total

1.  MicroRNA-125b-5p mediates post-transcriptional regulation of hepatitis B virus replication via the LIN28B/let-7 axis.

Authors:  Wanyu Deng; Xiaoyong Zhang; Zhiyong Ma; Yong Lin; Mengji Lu
Journal:  RNA Biol       Date:  2017-03-07       Impact factor: 4.652

Review 2.  Lin28 and let-7 in cell metabolism and cancer.

Authors:  Liem H Nguyen; Hao Zhu
Journal:  Transl Pediatr       Date:  2015-01

3.  Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling.

Authors:  Yuh-Ying Yeh; Hatice Gulcin Ozer; Amy M Lehman; Kami Maddocks; Lianbo Yu; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

4.  A cardiac myocyte-restricted Lin28/let-7 regulatory axis promotes hypoxia-mediated apoptosis by inducing the AKT signaling suppressor PIK3IP1.

Authors:  Shaurya Joshi; Jianqin Wei; Nanette H Bishopric
Journal:  Biochim Biophys Acta       Date:  2015-12-02

5.  Targeting LIN28B reprograms tumor glucose metabolism and acidic microenvironment to suppress cancer stemness and metastasis.

Authors:  Chong Chen; Lipeng Bai; Fengqi Cao; Shengnan Wang; Huiwen He; Mingcheng Song; Huilin Chen; Yan Liu; Jian Guo; Qin Si; Yundi Pan; Ruizhe Zhu; Tsung-Hsien Chuang; Rong Xiang; Yunping Luo
Journal:  Oncogene       Date:  2019-02-11       Impact factor: 9.867

Review 6.  MicroRNA regulation and analytical methods in cancer cell metabolism.

Authors:  Ling-Fei Zhang; Shuai Jiang; Mo-Fang Liu
Journal:  Cell Mol Life Sci       Date:  2017-03-20       Impact factor: 9.261

Review 7.  The role of microRNAs in hepatocyte metabolism and hepatitis B virus replication.

Authors:  Wanyu Deng; Mengji Lu
Journal:  Virol Sin       Date:  2016-12-28       Impact factor: 4.327

8.  Lin28 enhances de novo fatty acid synthesis to promote cancer progression via SREBP-1.

Authors:  Yang Zhang; Chenchen Li; Chuanzhen Hu; Qian Wu; Yongping Cai; Songge Xing; Hui Lu; Lin Wang; Linchong Sun; Tingting Li; Xiaoping He; Xiuying Zhong; Junfeng Wang; Ping Gao; Zachary J Smith; Weidong Jia; Huafeng Zhang
Journal:  EMBO Rep       Date:  2019-08-05       Impact factor: 8.807

Review 9.  Non-coding RNAs: the new central dogma of cancer biology.

Authors:  Phei Er Saw; Xiaoding Xu; Jianing Chen; Er-Wei Song
Journal:  Sci China Life Sci       Date:  2020-09-11       Impact factor: 6.038

Review 10.  Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression.

Authors:  Zhaoyong Li; Huafeng Zhang
Journal:  Cell Mol Life Sci       Date:  2015-10-23       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.